Restoring autonomic balance: Future therapeutic targets

EuroIntervention

Volumn 9, Issue , 2013, Pages R140-R148

  Sobotka, Paul A ^a   Osborn, John W ^b   Paton, Julian F R ^c  

^a CIBIEM INC   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Baroreceptor; Carotid body chemoreceptor; Kidney; Refractory hypertension; Splanchnic bed; Sympathetic

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIURETIC AGENT;

ABLATION THERAPY; ADRENERGIC SYSTEM; ANTIHYPERTENSIVE THERAPY; ARTICLE; AUTONOMIC NERVOUS SYSTEM; CAROTID BODY; CAROTID SINUS PRESSORECEPTOR REFLEX; GANGLIONECTOMY; HOMEOSTASIS; HUMAN; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; KIDNEY DENERVATION; NEUROMUSCULAR ELECTRICAL STIMULATION; NONHUMAN; RESISTANT HYPERTENSION; SIGNAL TRANSDUCTION; SPLANCHNIC NERVE; SYMPATHECTOMY; ANIMAL; BLOOD PRESSURE; DRUG RESISTANCE; HYPERTENSION; INNERVATION; KIDNEY; METHODOLOGY; PATHOPHYSIOLOGY; PRESSORECEPTOR REFLEX; REVIEW; TREATMENT OUTCOME; PROCEDURES; SURGERY;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BAROREFLEX; BLOOD PRESSURE; CAROTID BODY; DRUG RESISTANCE; HUMANS; HYPERTENSION; KIDNEY; SPLANCHNIC NERVES; SYMPATHECTOMY; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME;

EID: 84894367549     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV9SRA24     Document Type: Article

References (51)

1. Guyton AC, Coleman TG, Cowley AW Jr., Manning RD Jr., Norman RA Jr., Ferguson JD. A systems analysis approach to understanding long-range arterial blood pressure control and hypertension. Circ Res. 1974;35:159-76.
2. Averina VA, Othmer HG, Fink GD, Osborn JW. A new conceptual paradigm for the hemodynamics of salt-sensitive hypertension: a mathematical modeling approach. J Physiol. 2012;590: 5975-92.
3. Esler M. Pathophysiology of the human sympathetic nervous system in cardiovascular diseases: the transition from mechanisms to medical management. J Appl Physiol. 2010;108:227-37.
4. Fisher JP, Paton JF. The sympathetic nervous system and blood pressure in humans: implications for hypertension. J Hum Hypertens. 2012;26:463-75.
5. Paton JF, Li YW, Kasparov S. Reflex response and convergence of pharyngoesophageal and peripheral chemoreceptors in the nucleus of the solitary tract. Neuroscience. 1999;93:143-54.
6. Somers VK, Mark AL, Abboud FM. Interaction of baroreceptor and chemoreceptor reflex control of sympathetic nerve activity in normal humans. J Clin Invest. 1991;87:1953-7.
7. Osborn JW, Kuroki M. Sympathetic signatures of cardiovascular disease: a blueprint for development of targeted sympathetic ablation therapies. Hypertension. 2012;59:545-7.
8. Thrasher TN. Effects of chronic baroreceptor unloading on blood pressure in the dog. Am J Physiol. 2005;288:R863-71.
9. Lohmeier TE, Iliescu R. Chronic lowering of blood pressure by carotid baroreflex activation: mechanisms and potential for hypertension therapy. Hypertension. 2011;57:880-6.
10. Heusser K, Tank J, Engeli S, Diedrich A, Menne J, Eckert S, Peters T, Sweep FC, Haller H, Pichlmaier AM, Luft FC, Jordan J. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension. 2010;55:619-26.
11. Bakris GL, Nadim MK, Haller H, Lovett EG, Schafer JE, Bisognano JD. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term followup in the Rheos Pivotal Trial. J Am Soc Hypertens. 2012;6:152-8.
12. Hoppe UC, Brandt MC, Wachter R, Beige J, Rump LC, Kroon AA, Cates AW, Lovett EG, Haller H. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens. 2012;6:270-6.
13. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M; Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903-9.
14. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275-81.
15. Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension. 1995;25:878-82.
16. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, Dietl KH, Rahn KH. Sympathetic nerve activity in endstage renal disease. Circulation. 2002;106:1974-99.
17. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med. 2009;361:932-4.
18. Hering D, Lambert EA, Marusic P, Walton AS, Krum H, Lambert GW, Esler MD, Schlaich MP. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension. 2013;61:457-64.
19. Brinkmann J, Heusser K, Schmidt BM, Menne J, Klein G, Bauersachs J, Haller H, Sweep FC, Diedrich A, Jordan J, Tank J. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients: prospective case series. Hypertension. 2012;60:1485-90.
20. Chan K, Ng FL, Saxena M, Collier D, Matson M, Jain A, Caulfield M, Lobo M. Renal denervation in resistant hypertension-A prospective case series. J Hum Hypertension. 2012;26:S16.
21. Prochnau D, Lucas N, Kuehnert H, Figulla HR, Surber R. Catheterbased renal denervation for drug-resistant hypertension by using a standard electrophysiology catheter. EuroIntervention. 2012;7:1077-80.
22. Vase H, Mathiassen ON, Kaltoft A, Pedersen EB, Christensen KL, Buus NH, Lederballe O, Lassen JF, Bøtker HE, Thuesen L. Catheter-based renal denervation for treatment of resistant hypertension. Dan Med J. 2012;59:A4439.
23. Mahfoud F, Bohm M. Rump LC, Venend O, Schmieder RE, Kintscher U. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients; prospective case series. Hypertension. 2013;61:e17.
24. Grimson KS, Orgain ES, Anderson B, D'Angelo GJ. Total thoracic and partial to total lumbar sympathectomy, splanchnicectomy and celiac ganglionectomy for hypertension. Ann Surg. 1953;138:532-47.
25. Smithwick RH. Splanchnicectomy for essential hypertension; results in 1,266 cases. J Am Med Assoc. 1953;152:1501-4.
26. Foss JD, Fink GD, Osborn JW. Reversal of genetic salt-sensitive hypertension by targeted sympathetic ablation. Hypertension. 2013;61:806-11.
27. Boegehold MA, Huffman LJ, Hedge GA. Peripheral vascular resistance and regional blood flows in hypertensive Dahl rats. Am J Physiol. 1991;261:R934-R938.
28. Tomohiro A, Kimura S, He H, Fujisawa Y, Nishiyama A, Kiyomoto K, Aki Y, Tamaki T, Abe Y. Regional blood flow in Dahl-Iwai salt-sensitive rats and the effects of dietary L-Arginine supplementation. Am J Physiol. 1997;272:R1013-9.
29. Pinto YM, Pau LM, Ganten D. Lessons from rat models of hypertension: from Goldblatt to genetic engineering. Cardiovasc Res. 1998;39:77-88.
30. Fink GD, Osborn JW. The splanchnic circulation. Primer on the autonomic nervous system. Robertson D, Biaggioni I, Burnstock G, Low PA and Paton JFR, Oxford: Academic Press; 2012;211-4.
31. King AJ, Osborn JW, Fink GD. Splanchnic circulation is a critical neural target in angiotensin II salt hypertension in rats. Hypertension. 2007;50:547-56.
32. Osborn JW, Fink GD, Kuroki MT. Neural mechanisms of angiotensin II-salt hypertension: implications for therapies targeting neural control of the splanchinc circulation. Curr Hypertens Rep. 2011;13:221-8.
33. King AJ, Fink GD. Chronic low-dose angiotensin II infusion increases venomotor tone by neurogenic mechanisms. Hypertension. 2006;48:927-33.
34. Osborn JW, Fink GD. Region specific changes in sympathetic nerve activity in AngII-salt hypertension. Exp Physiol. 2010;95:61-8.
35. Zubcevic J, Waki H, Raizada MK, Paton JF. Autonomicimmune-vascular interaction: an emerging concept for neurogenic hypertension. Hypertension. 2011;57:1026-33.
36. Clark JA, de Burgh Daly M, Ead HW. Vascular analysis of the carotid body in the spontaneously hypertensive rat. In: Neurobiology and Cell Physiology of Chemoreception. Ed: PG Data. Plenum Press 1993, Chap 1, pp3-8.
37. Ponte J, Purves MJ. The role of the carotid body chemoreceptors and carotid sinus baroreceptors in the control of cerebral blood vessels. J Physiol. 1974;237:315-40.
38. Koshiya N, Huangfu D, Guyenet PG. Ventrolateral medulla and sympathetic chemoreflex in the rat. Brain Res. 1993;609:174-84.
39. Zoccal DB, Simms AE, Bonagamba LG, Braga VA, Pickering AE, Paton JF, Machado BH. Increased sympathetic outflow in juvenile rats submitted to chronic intermittent hypoxia correlates with enhanced expiratory activity. J Physiol. 2008; 586:3253-65.
40. Fletcher EC, Lesske J, Behm R, Miller CC 3rd, Stauss H, Unger T. Carotid chemoreceptors, systemic blood pressure, and chronic episodic hypoxia mimicking sleep apnea. J Appl Physiol. 1992;72:1978-84.
41. Tan ZY, Lu Y, Whiteis CA, Simms AE, Paton JF, Chapleau MW, Abboud FM. Chemoreceptor hypersensitivity, sympathetic excitation, and overexpression of ASIC and TASK channels before the onset of hypertension in SHR. Circ Res. 2010;106;536-45.
42. Somers VK, Mark AL, Abboud FM. Potentiation of sympathetic nerve responses to hypoxia in borderline hypertensive subjects. Hypertension. 1988;11:608-12.
43. Trzebski A, Tafil M, Zoltowski M, Przybylski J. Increased sensitivity of the arterial chemoreceptor drive in young men with mild hypertension. Cardiovasc Res. 1982;16:163-72.
44. Abdala AP, McBryde FD, Marina N, Hendy EB, Engelman ZJ, Fudim M, Sobotka PA, Gourine AV, Paton JF. Hypertension is critically dependent on the carotid body input in the spontaneously hypertensive rat. J Physiol. 2012;590:4269-77.
45. Siski M, Lewandowski J, Przybylski J, Bidiuk J, Abramczyk P, Ciarka A, Gaciong Z. Tonic activity of carotid body chemoreceptors contributes to the increased sympathetic drive in essential hypertension. Hypertens Res. 2012;35:487-91.
46. Despas F, Lambert E, Vaccaro A, Labrunee M, Franchitto N, Lebrin M, Galinier M, Senard JM, Lambert G, Esler M, Pathak A. Peripheral chemoreflex activation contributes to sympathetic baroreflex impairment in chronic heart failure. J Hypertension. 2012;30:753-60.
47. Paton JF, Sobotka PA, Fudim M, Engelman ZJ, Hart CJ, McBryde FD, Abdala AP, Marina N, Gourine AV, Lobo M, Patel N, Burchell A, Ratcliffe L, Nightingale A. The carotid body as a therapeutic target for treatment of sympathetically mediated diseases. Hypertension. 2013;61:5-13.
48. Narkiewicz K, van de Borne PJ, Pesek CA, Dyken ME, Montano N, Somers VK. Selective potentiation of peripheral chemoreflex sensitivity in obstructive sleep apnea. Circulation. 1999;99:1183-9.
49. Smith CA, Nakayama H, Dempsey JA. The essential role of carotid body chemoreceptors in sleep apnea. Can J Physiol Pharmacol. 2003;81:774-9.
50. Nakayama K. Surgical removal of the carotid body for bronchial asthma. Dis Chest. 1961;40:595-604.
51. Patel NK, Javed S, Khan S, Papouchado M, Malizia AL, Pickering AE, Paton JF. Deep brain stimulation relieves refractory hypertension. Neurology. 2012;76:405-7.